SmiLe Inject Capital boosts life science innovation with €800K investment in pioneering startups

SmiLe Inject Capital, Sweden’s only angel investment company dedicated to early-stage life science companies has announced a strategic investment of €800K in three pioneering life science startups: Uman Sense, Nygen Analytics, and Aligned Bio.

SmiLe Inject Capital plays a pivotal role in SmiLe’s ecosystem, which focuses on commercializing life science innovations with the potential to improve global health. The latest investments bring the total number of companies in SmiLe Inject Capital’s portfolio to ten, demonstrating the firm’s commitment to nurturing groundbreaking technologies. Let’s take a look at these three startups:

Uman Sense: A new approach to stroke prevention

Uman Sense has developed an innovative wristband known as the Stroke Alarm, designed to continuously monitor individuals at high risk for stroke. This technology, created in collaboration with leading medical experts, aims to provide early alerts in the event of a suspected stroke, enabling rapid medical intervention.

Stroke is a major health issue, being one of the leading causes of permanent disability in adults and the second leading cause of death in the Western world. To support the further development of Stroke Alarm and its upcoming launch in the European market, SmiLe Inject Capital has invested over €260K, contributing to the million euros raised by Uman Sense.

Nygen Analytics: Transforming genomics data analysis

Nygen Analytics is revolutionizing the field of genomics with its cloud-based, large language model (LLM)-driven platform, which simplifies the analysis of vast amounts of gene data. This platform significantly reduces the need for extensive computing resources and specialized expertise, allowing researchers in academia, biotech, and the pharmaceutical industry to gain deep insights more efficiently.

According to SmiLE, the company’s technology is poised to play a crucial role in the development of cell and gene therapies, a rapidly expanding area of medical research. To support Nygen Analytics’ continued technical development and market positioning, SmiLe Inject Capital has invested over €176K  as part of the €660K funding round.

Aligned Bio: Advancing biosensor technology

Aligned Bio is at the forefront of developing a nanowire-based technology platform for biosensors, with applications in both disease diagnostics and genome sequencing. This technology offers unparalleled sensitivity, with the ability to analyze longer DNA fragments and detect diseases like cancer with 10-100 times greater sensitivity compared to existing commercial sensors.

Furthermore, this technology promises to be indispensable in the next generation of genome sequencing. SmiLe Inject Capital has committed over €350K to Aligned Bio to help scale up production and continue the development of this groundbreaking technology.

Thomas Unt, CEO of SmiLe Inject Capital and business development coach at SmiLe said: “SmiLe Inject has seen great potential for rapid commercial success in all these investments. All companies are close to market launch and have been working for a long time with strategic partners. Our hope is that their respective innovative technologies and strong teams have the potential to reach critical milestones to ensure commercial impact.”